← Back to Search

Adherence Strategies for Lung Cancer Screening

N/A

Recruiting

Led By Katharine Rendle, PhD,MSW,MPH

Research Sponsored by Abramson Cancer Center at Penn Medicine

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients eligible for LCS based on 2021 US Preventive Services Task Force (USPSTF) population guidelines (aged 50-80; smoking history of 20-pack years; smoked within the last 15 years)

Patients who have not been diagnosed with lung cancer

Timeline

Screening 3 weeks

Treatment Varies

Follow Up initial measurement will occur 3 months after randomization

Awards & highlights

Study Summary

This trial is testing strategies to help people get lung cancer screening & diagnostic follow-up. Patients & clinicians will be interviewed after to gain insight into what works.

Who is the study for?

This trial is for patients aged 50-80 with a history of significant smoking who haven't been diagnosed with lung cancer and are non-adherent to lung cancer screening. It's also for clinicians in the University of Pennsylvania Health System who treat such patients and have not opted out.Check my eligibility

What is being tested?

The study tests whether 'nudges' (gentle encouragements) can improve how well both doctors and patients stick to recommended lung cancer screenings. The effectiveness will be measured, followed by interviews to understand barriers or enhancers.See study design

What are the potential side effects?

Since this trial involves behavioral interventions rather than medications, traditional side effects are not applicable. However, participants may experience increased healthcare engagement or changes in their interaction with healthcare providers.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 50-80 years old with a history of heavy smoking.

Select...

I have never been diagnosed with lung cancer.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ initial measurement will occur 3 months after randomization

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~initial measurement will occur 3 months after randomization

This trial's timeline: 3 weeks for screening, Varies for treatment, and initial measurement will occur 3 months after randomization for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of completed annual LCS in patients with a negative baseline screen (Lung Imaging Reporting and Data System (Lung-RADS) 1 or 2).

Number of completed recommended diagnostic follow-up scans or procedures in patients with a positive baseline screen (Lung-RADS 3 or 4a).

Secondary outcome measures

Reach

Other outcome measures

Number of downstream imaging and diagnostic procedures

Number of lung cancer diagnoses

Rate of false-positive screens

Trial Design

4Treatment groups

Experimental Treatment

Active Control

Group I: Patient Nudge OnlyExperimental Treatment1 Intervention

Patients in this arm will receive messaging designed to increase awareness about the importance of annual screening and recommended follow-up. Clinicians will receive usual care.

Group II: Clinician Nudge OnlyExperimental Treatment1 Intervention

Clinicians in this arm will not be prompted by a pended order when a patient is due for lung cancer screening or diagnostic follow-up. Patients will receive usual care.

Group III: Clinician Nudge + Patient NudgeExperimental Treatment2 Interventions

An EHR-prompt (pended order) will prompt clinicians in this arm when a patient is due for lung cancer screening or diagnostic follow-up. Patients in this arm will receive messaging designed to increase awareness about the importance of annual screening and recommended follow-up

Group IV: Usual care (no nudges)Active Control1 Intervention

Patients and clinicians in this arm will receive usual care.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Clinician Nudge

2020

N/A

~10730

Patient Nudge

2020

N/A

~10730

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

National Comprehensive Cancer NetworkNETWORK

115 Previous Clinical Trials

6,235 Total Patients Enrolled

Abramson Cancer Center at Penn MedicineLead Sponsor

387 Previous Clinical Trials

144,244 Total Patients Enrolled

AstraZenecaIndustry Sponsor

4,272 Previous Clinical Trials

288,611,275 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the enrollment for this clinical trial limited to applicants below a certain age?

"This trial is restricted to those between the ages of 50 and 80. There are 47 trials welcoming minors while 1673 studies seek participants over 65 years old."

Answered by AI

How many participants can enroll in this trial?

"Affirmative. The clinical trial is actively recruiting for 1400 participants as per the data hosted on clinicaltrials.gov, which was initially posted October 18th 2023 and revised November 10th of the same year. One medical centre will be responsible for enrolling all patients in this study."

Answered by AI

Are there any open enrollment periods for this research endeavor?

"Affirmative. Research hosted on clinicaltrials.gov verifies that this trial, which was initially listed on October 18th 2023, is actively searching for patients. Specifically 1400 individuals need to be recruited from 1 medical centre."

Answered by AI

Might I be a candidate for participating in this research?

"This research endeavour is searching for 1400 lung cancer patients aged 50 to 80, who have undergone Low-Dose Computed Tomography (LDCT) in the years 2019 - 2022. Additionally, all participants must have a smoking history of 20 pack-years and smoked within the last 15 years; they should be eligible for LCS based on USPSTF guidelines and remain eligible during enrolment period. Furthermore, their clinician must not opt out from study participation nor can the patient themself decline involvement in this clinical trial."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Increasing Adherence to Lung Cancer Screening

Katharine Rendle 2023. "Increasing Adherence to Lung Cancer Screening". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05832008.